Bangavax first buzzed with hope, then fizzled

 
Obaidur Masum, Senior Correspondent, 
bdnews24.com
Published: 06 May 2021 11:42 AM BdST
Updated: 06 May 2021 11:51 AM BdST
Globe Biotech, a Bangladeshi company, applied for permission to begin clinical trials of its COVID-19 vaccine candidate ‘Bangavax’ in January. But, over three months later, it has yet to receive the approval of the Bangladesh Medical Research Council.
");
}
As trials have yet to begin, it means the effectiveness of the domestically produced vaccine is still unknown.
Globe Biotech applied for approval to begin testing on humans, known as a clinical trial, on Jan 17.
According to the rules, applications are first screened by the BMRC’s National Research Ethics Committee. If the BMRC gives its ethical consent, it goes to the Directorate General of Drug Administration. There it will wait for the consideration and approval of the National Clinical Trial Advisory Committee.

Related Keywords

Ruhul Amin ,Syed Modasser Ali ,Mohammad Mohiuddin ,National Research Ethics Committee ,Globe Pharmaceuticals ,World Health Organization ,Drug Administration ,Clinical Research Organisation Ltd On Jan ,National Clinical Trial Advisory Committee ,Research Ethics ,Directorate General ,National Clinical Trial Advisory ,Clinical Research Organisation Ltd ,Globe Biotech ,Corona Virus ,Pandemic ,Vaccine ,Bangavax ,Lobe Pharma ,Clinical Trials ,Hmrc ,ருஹுல் அமின் ,முகமது மொஹ்ிுட்தின் ,தேசிய ஆராய்ச்சி நெறிமுறைகள் குழு ,பூகோளம் மருந்துகள் ,உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் ,ஆராய்ச்சி நெறிமுறைகள் ,இயக்குநரகம் ஜநரல் ,பூகோளம் பயோடெக் ,கொரோனா வைரஸ் ,ம்ர்க் ,